Last reviewed · How we verify
Chidamide in combination with Ivonescimab — Competitive Intelligence Brief
phase 2
Small molecule
Live · refreshed every 30 min
Target snapshot
Chidamide in combination with Ivonescimab (Chidamide in combination with Ivonescimab) — Guangdong Association of Clinical Trials.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Chidamide in combination with Ivonescimab TARGET | Chidamide in combination with Ivonescimab | Guangdong Association of Clinical Trials | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Chidamide in combination with Ivonescimab CI watch — RSS
- Chidamide in combination with Ivonescimab CI watch — Atom
- Chidamide in combination with Ivonescimab CI watch — JSON
- Chidamide in combination with Ivonescimab alone — RSS
Cite this brief
Drug Landscape (2026). Chidamide in combination with Ivonescimab — Competitive Intelligence Brief. https://druglandscape.com/ci/chidamide-in-combination-with-ivonescimab. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab